Sadat Sams M A, Saeidnia Soodabeh, Nazarali Adil J, Haddadi Azita
3D01.01, D Wing Health Sciences, 107 Wiggins Road, Saskatoon SK, S7N 5E5, Canada.
Curr Cancer Drug Targets. 2015;15(1):71-86. doi: 10.2174/1568009615666150105115047.
Nanotechnology has revolutionized fundamental opportunities for higher specific drug delivery with minimum side effects. Since its inception, the goal of nanotechnology has been to advance effective and reliable systems for precise anti-cancer therapy and diagnosis. To accomplish this goal, bio-conjugation strategies of therapeutic agents loaded nanoparticles with monoclonal antibodies or their analogues have demonstrated a targeted approach both in vitro and in vivo. In this review, we primarily focus on the specific recognition of HER2 receptors of HER2 overexpressed tumor cells, and evaluate anti-HER2 monoclonal antibody as an effective tool for active targeting. Currently, a variety of nanoparticle systems are under both preclinical and clinical trials for targeting to HER2 positive breast cancer. Different nanotechnology scaffolds including liposomes, dendrimers, micelles, polymeric and inorganic nanoparticles that have higher flexibility for macromolecular synthesis and versatile functionalizing properties have been reviewed in this study. Continuing advances in anti-HER2 functionalized nanoparticles have good potential to lead to the development of nano-therapy against HER2 positive breast cancer.
纳米技术为实现更高的特异性药物递送且副作用最小化带来了根本性变革。自诞生以来，纳米技术的目标一直是推进有效且可靠的系统，用于精准的抗癌治疗与诊断。为实现这一目标，将治疗剂负载于纳米颗粒上并与单克隆抗体或其类似物进行生物偶联的策略，已在体外和体内展示出一种靶向方法。在本综述中，我们主要聚焦于HER2过表达肿瘤细胞中HER2受体的特异性识别，并评估抗HER2单克隆抗体作为主动靶向的有效工具。目前，多种纳米颗粒系统正处于针对HER2阳性乳腺癌的临床前和临床试验阶段。本研究综述了不同的纳米技术支架，包括脂质体、树枝状大分子、胶束、聚合物纳米颗粒和无机纳米颗粒，它们在大分子合成方面具有更高的灵活性以及多功能化特性。抗HER2功能化纳米颗粒的持续进展很有可能促成针对HER2阳性乳腺癌的纳米治疗的发展。
